Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study
Karolinska Inst, Dept Med Solna, Stockholm, Sweden.;Stockholm Cty Council, Dept Healthcare Dev, Stockholm, Sweden..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Cardiovascular epidemiology.
Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
Karolinska Inst, Dept Med Solna, Stockholm, Sweden.;Karolinska Univ Hosp, Clin Pharmacol, Stockholm, Sweden..
Show others and affiliations
2018 (English)In: European Journal of Clinical Pharmacology, ISSN 0031-6970, E-ISSN 1432-1041, Vol. 74, no 2, p. 219-226Article in journal (Refereed) Published
Abstract [en]

Purpose: To describe patients initiating dimethyl fumarate (DMF) and measure persistence with DMF, discontinuation, and switching in treatment-na < ve DMF patients and patients switching to DMF from other multiple sclerosis disease-modifying treatments (DMTs).

Methods: A population-based cohort study of all Stockholm County residents initiating DMF from 9 May 2014 until 31 May 2017. All data were derived from a regional database that collects individual-level data on healthcare and drug utilization of all residents. The study outcomes were persistence with DMF and DMF discontinuation and switching to other DMTs. Persistence was measured as the number of days until either DMF discontinuation (treatment gap ae<yen> 60 days) or switching to another DMT.

Results: The study included 400 patients (median follow-up = 2.5 years). The majority had previously been treated with other DMTs (61%). Throughout the follow-up period, 124 patients (31%) discontinued DMF and 114 patients (29%) switched treatment. Overall, 34% of patients initiating DMF stopped treatment within 1 year and only 43% of patients remained on DMF at 2 years from treatment initiation.

Conclusions: DMF had a rapid market uptake likely due to high expectations held by both patients and clinicians. However, persistence with DMF in routine clinical practice was found to be low.

Place, publisher, year, edition, pages
SPRINGER HEIDELBERG , 2018. Vol. 74, no 2, p. 219-226
Keywords [en]
Multiple sclerosis, relapsing-remitting, Dimethyl fumarate, Drug utilization, Persistence
National Category
Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:uu:diva-341563DOI: 10.1007/s00228-017-2366-4ISI: 000419893700009PubMedID: 29128972OAI: oai:DiVA.org:uu-341563DiVA, id: diva2:1182023
Available from: 2018-02-12 Created: 2018-02-12 Last updated: 2018-02-12Bibliographically approved

Open Access in DiVA

fulltext(503 kB)51 downloads
File information
File name FULLTEXT01.pdfFile size 503 kBChecksum SHA-512
6442288d62aa035493adffa849d83e17cf71335e57ae96a762b809de7ae8e65b5105f90759283bc1c8adc1eefc8d3a16a8c2d7c728878a27a85fb7ef89e9752f
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Cars, Thomas
By organisation
Cardiovascular epidemiology
In the same journal
European Journal of Clinical Pharmacology
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 51 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 27 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf